绿叶制药抗抑郁1类创新药(LY03021)获准开展临床试验

格隆汇资讯
11 Nov 2024

格隆汇11月11日丨绿叶制药(02186.HK)宣布,集团的1类创新药LY03021已获得中国国家药品监督管理局药品审评中心批准开展临床试验,拟用于治疗抑郁症。LY03021为去甲肾上腺素转运体(“NET”)╱多巴胺转运体("DAT")抑制剂、γ-氨基丁酸A受体正向变构调节剂(GABAAR PAM)。该产品基于集团新分子实体╱新治疗实体技术平台(NCE/NTE)自主开发,是全新的三靶点作用机制...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10